|Bid||83.06 x 800|
|Ask||83.07 x 800|
|Day's Range||82.53 - 83.31|
|52 Week Range||59.80 - 84.27|
|Beta (3Y Monthly)||0.29|
|PE Ratio (TTM)||26.22|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||2.20 (2.78%)|
|1y Target Est||88.93|
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...
U.S. drugmakers on Friday filed a lawsuit to prevent the companies from disclosing the list price of prescription drugs in direct-to-consumer television advertisements as per a newly proposed government regulation. The lawsuit was jointly filed by Amgen Inc, Merck & Co Inc, Eli Lilly and Co and the Association Of National Advertisers in the U.S. district court in Columbia. The new regulation on advertisement, which was finalized on May 8 by the U.S. Department of Health and Human Services (HHS) and takes effect in July, is part of the government's efforts to bring down costs for U.S. consumers.
A World Health Organisation (WHO) advisory panel decided on Friday not to declare an international public health emergency over the Ebola outbreak in Congo and Uganda, saying that the criteria had not been met. Authorities in Uganda, where two members of the same family died this week from the disease, have drawn up a list of 98 contacts, or contacts of contacts, potentially exposed to the Ebola virus, but only 10 are considered "high risk", WHO expert Dr Mike Ryan told a news conference at WHO headquarters in Geneva.
Analysts say that the event will be vital for the pharmaceutical company as it seeks to show investors it can build on a strong run in recent years.
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
The companies said they would work with consultancy KPMG to create a shared blockchain network that will allow real-time monitoring of products in the pharmaceutical supply chain. The project has been authorized under the U.S. Drug Supply Chain Security Act (DSCSA) that was set up to increase regulatory oversight of counterfeit, stolen, contaminated or otherwise harmful drugs. The FDA has previously used the DSCSA to issue a warning letter to drug distributor McKesson Corp for violations involving opioid medications.
ARMONK, N.Y., NEW YORK, KENILWORTH, N.J., and BENTONVILLE, Ark., June 13, 2019 /PRNewswire/ -- IBM (NYSE: IBM), KPMG, Merck (MRK), and Walmart (WMT) today announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the U.S. Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the United States.
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
A five-year-old boy has died from Ebola in Uganda and two more people have been infected in the first known cases of the virus crossing a border since the outbreak began in eastern Congo last year. Health experts on Wednesday were racing to discover how the boy’s relatives entered Uganda on June 9 and with whom they might have come into contact. Jeremy Farrar, director of Wellcome, a UK health charity, said that the epidemic, the second worst in history, had reached “a truly frightening phase”.
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Part of what attracted ILÚM to Albany from New Jersey is the state's Wadsworth Center public health lab, which studies disease outbreaks.
Stoke now hopes to raise $123 million when it launches on the Nasdaq market in the coming weeks, according to documents newly filed with the SEC. It originally had filed plans for an $86.25 million initial public offering last month. Stoke could be the fifth Massachusetts biotech to go public this year.
Keytruda, Merck & Co., Inc. (NYSE: MRK )'s flagship cancer immunotherapy, has secured FDA clearance for two more indications, cementing its positioning as the top oncology drug and expanding its lead over ...
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Merck & Co Inc NYSE:MRKView full report here! Summary * Perception of the company's creditworthiness is positive * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MRK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MRK had net inflows of $5.81 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. MRK credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer. The drug was approved for use as a monotherapy, as well as in combination with a common chemotherapy regimen, to treat previously untreated patients with head and neck squamous cell carcinoma, Merck said. The approval is based on results from a late-stage trial, where Keytruda showed a significant improvement in overall survival in cancer patients, Merck said.